Taiwan: Pharma at the Tipping Point - Pharmaceutical Executive


Taiwan: Pharma at the Tipping Point

Pharmaceutical Executive


A surprising fact about Taiwan is that it has become something of a hub in Asia for late-phase clinical trials. The NIH reports that in 2009, Taiwan conducted 1,574 clinical trials, more than China (1,427), India (1,143), Korea (1,510), and Japan (1,337). Alex Chang of Novartis Taiwan explains why so many MNCs are ready to conduct trials here: "Regulation has become very friendly—clinical trial approval takes a maximum of three months to get. This is still longer than South Korea, but much better than China. The government is ready, infrastructure is ready, 99 percent of hospitals are ready, CROs are ready, and patients are ready." However, by far the majority of these trials are Phase III: companies use late-phase trials as a way to gain speedier market access. As president of Academia Sinica Chi-huey Wong puts it: "We need to encourage these companies to look to Taiwan as a locale for conducting more early-phase trials. This is where Taiwan's real strengths lie."

Albert Liou, Parexel International
In many respects the "father" of Taiwan's clinical trial success, Albert Liou, founder of Apex International (later acquired by Parexel, for whom Liou is corporate vice president and general manager of the Asia Pacific region), is keen to stress that moving to early-phase clinical trials will not be the only challenge that Taiwan will face in the years to come. "Although the clinical research environment has a good level of quality, Taiwan is still small in terms of size. Out of the 100 hospitals that are involved in clinical studies, only the top 20 are prominent enough to attract global clinical trials. The other 80 hospitals in the country are just beginning to become aware of or involved in clinical research, and so are less experienced."

The room for growth may come as a surprise to those looking at the 2009 figures for clinical trials conducted in the country, but the Taiwanese government has recognized the potential for developing this sector into one of the country's key industrial strengths. By creating the title of "Centers of Excellence" for those hospitals and medical centers that excelled early and provided incentives for others to reach this position, the Taiwanese government is hoping that more institutes will look to clinical trials as a source of profit and a way to bring the latest medical innovations to their patients. The natural result of this will be more foreign investment coming into Taiwan from Big Pharma. Liou sums it up by saying, "A key factor in attracting clinical trials to Taiwan is that quality data can be collected in the market, coupled with other benefits such as fast recruitment and overall efficiency."

Mark Yang, General Manager of Hospira Taiwan
"For drug companies," says Chung Y Hsu, CEO of China Medical University Hospital (CMUH), one of Taiwan's Centers of Excellence for clinical trials, "the most important aspect of any clinical study comes down to one sentence: Time is money." Hsu holds to the philosophy that Taiwanese hospitals need to be as compliant as possible with pharmaceutical companies in order to attract both their customers and their trust. "These relationships are not built through sales and marketing departments, but rather through a hospital's track record. When we enroll the patients at very good speeds, then the company has a good experience with us. The next time we collaborate, we are able to streamline our procedures because of our working experience, which makes the experience of working with CMUH get better every time. We let our performance speak for itself."

CMU Hospital, or "healthcare system," is part of the China Medical University complex. Chairman of both China Medical University and CMU Healthcare System's Chang-hai Tsai explains the origins of the organization: "CMU, as China implies, was funded initially for traditional Chinese medicine (TCM). It has become a medical university with balanced advances on both TCM and Western medicine. With emerging emphasis on alternative and complementary medicine in Western countries and development of novel drugs from natural products, CMU is in a unique position in the new era of pharmaceutical R&D."


blog comments powered by Disqus

Source: Pharmaceutical Executive,
Click here